The clinical potential of Deprenyl in neurologic and psychiatric disorders
This article reviews the results of clinical studies with Deprenyl in various neurologic and psychiatric disorders except Parkinson’s disease. Promising results could be observed both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one study of Tourette’s syndrome including attention hyperactivity disorders using an average dosis of 8.1 mg/ day. Controversial results were reported for Alzheimer’s disease. On the one hand significant improvement of cognitive functions was found by various authors. On the other hand in a more recent study no effect on the progression of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.
KeywordsAmyotrophic Lateral Sclerosis Negative Symptom Progressive Supranuclear Palsy Tardive Dyskinesia Progressive Supranuclear Palsy
Unable to display preview. Download preview PDF.
- Agid Y, Javoy-Agid F, Ruberg M, et al (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 45: 191–206Google Scholar
- Agnoli A, Martucci N, Fabbrini G, et al (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109–114Google Scholar
- Baldessarini RJ (1979) Neurological toxicology of antipyschotic drugs. McLean Hosp J 4:2–19Google Scholar
- Chouinard G, Jones BD, Annable L (1980) L-dopa in neuroleptic induced extrapyramidal symptoms. 35th Annual Convention of Society of Biological Psychiatry of USA, BostonGoogle Scholar
- Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE (1994) Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm [Suppl] 41: 237–241Google Scholar
- Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Monoamine oxidase — new vistas. Raven Press, New York, pp 393–408Google Scholar
- Mendis N, Pare CMB, Sandler M, et al (1981) Deprenyl in the treatment of depression. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. John Wiley and Sons, Chichester, pp 171–176Google Scholar
- Mitchell JD, Houghton E, Kilshow J, et al (1993) Free radicals, sporadic motor neurone disease and selegiline. Symposium on Neuroprotection and clinical trials in MND/ ALS, Paris (Abstract)Google Scholar
- Quitkin FM, Liebowitz MR, Stewart JW, et al (1985) Deprenyl in atypical depressives. I. Clinical efficacy. Proceedings of the International Symposium in Deprenyl. Chinoin, Budapest, pp 115–119Google Scholar
- Roselar SE, Langdon N, Lock CB, Jenner P, Parkes JD (1987) Selegiline in narcolepsy. Sleep 10(5): 491–495Google Scholar
- Schachter M, Price PA, Parkes JD (1979) Deprenyl in narcolepsy. Lancet i: 831–832Google Scholar
- Tringer L, Haits G, Varga E (1971) The effect of L-E-280 (L-phenylisopropyl-methyl-propinylamine) in depression. Soc Pharmacol Hungarica, Budapest, pp 111–113Google Scholar